Hologic buys Biotheranostics molecular testing firm

By LabPulse.com staff writers

January 5, 2021 -- Hologic continues to start 2021 with a bang. The company announced on January 5 that it is acquiring Biotheranostics, a developer of molecular tests for breast and metastatic cancer, for $230 million.

Acquiring Biotheranostics allows Hologic to enter the fast-growing oncology molecular testing market, according to the firm. It also fits well with the company's existing focus on women's health.

Biotheranostics operates a CLIA-certified lab that will help Hologic develop new capabilities and accelerate market development of new diagnostic tests. Biotheranostics will become part of Hologic's Diagnostics division.

Biotheranostics has developed two polymerase chain reaction gene expression tests, Breast Cancer Index for women being treated with endocrine therapy for their breast cancer, and CancerType ID, which can be used in the diagnosis of tumor type and subtypes representing 95% of all solid tumors.

Biotheranostics generated about $33 million in revenue in 2020, according to the companies. The deal is expected to close in February 2021, and it is subject to customary closing conditions.

The acquisition is the second for Hologic in recent weeks. The company announced its acquisition of biopsy marker developer Somatex Medical Technologies on January 4.

FDA OK's new claim for Hologic's HIV assay
The U.S. Food and Drug Administration (FDA) has approved Hologic's diagnostic claim for its HIV-1 viral load monitoring assay, the Aptima HIV-1 Quant...
Hologic wins CE Mark for cervical cancer screening system
Hologic has secured the CE Mark for its Genius Digital Diagnostics digital cytology platform for cervical cancer screening. The system combines a new...
Hologic gets CE Mark for breast specimen x-ray system
Hologic has received the CE Mark for its Faxitron Path+ specimen radiography system, which can be used for breast tissue imaging. The system consists...
Hologic Q4 sales boom on diagnostics revenues
Booming revenues in its Molecular Diagnostics segment due to the COVID-19 pandemic helped Hologic post a 55.6% increase in sales for its fourth quarter....
Hologic scores $119M COVID-19 testing contract
The U.S. government has awarded a $119 million contract to Hologic to expand its production capacity for COVID-19 molecular tests.

Copyright © 2021 LabPulse.com

Last Updated ls 1/5/2021 5:02:07 PM